We present a new functional assay for the first complement component (Cl) in plasma, based on its activation by inhibition of the Cl -esterase inhibitor (Cl -inh) when monospecific antiserum to Cl -inh is added to the plasma. After maximal activation, we can determine the concentration of activated Cl by using an amidolytic rate assay with a chromogenic substrate. We have optimized the assay conditions with respect to incubation time, concentration of antiserum to Cl-inh, ionic strength, and pH. Our method determines specifically the concentration in plasma of free activated Cl, not complexes of activated Cl with Cl-inh, and is not influenced by the concentration of Cl-inh in the test sample. Concentrations of Cl correlated significantly with activities determined by a hemolytic assay (r = 0.55, t = 4.09, P <0.001). The estimated interassay CV was 5% and the intra-assay CV was 1%. The sensitivity, imprecision, and practical test performance of our assay are superior to those of conventionally used hemolytic assays.
The first component of the classical complement pathway, Cl, a macromolecular complex of 750 kDa, consists of the three subunits Clq, Clr, and Cia and is dependent on the presence of Ca2 for assembly (1) .' Immune-complex activation of this pathway is believed to be initiated through the binding of C lq to antibody, causing a conformational change of Clq that results in the subsequent activation of C lr (1) . Cli converts all Cis to Cli, which in turn cleaves the other components C4 and C2 of the classical complement pathway (1) . The initial activation of the classical complement pathway is regulated by the Ci-esterase inhibitor (C1-inh), which binds to CIr and CIs and thereby renders these activators enzymatically inactive (2) . Activation of the classical pathway reportedly contributes to the pathogenesis of many acquired diseases, including sepsis and connective tissue diseases (3) (4) (5) (6) (7) (8) . Furthermore, the extent of complement activation may correlate with the clinical deterioration in patients with systemic lupus erythematosus (9) . Determination of the functional concentration of Cl in blood is at present based on hemolytic assays (10-14) usually carried out in serum samples. As we demonstrate in the present study, the preparation of serum causes spontaneous activation of Cl. This observation may help to explain why hemolytic assays are difficult to standardize, in addition to being time-consuming and requiring multiple reagents. We have, therefore, developed the conditions in plasma for a new, rapid, and precise functional assay of Cl that is not biased by spontaneous in vitro activation. We activate Cl in the plasma sample by inhibiting the C1-inh (2, 15) with specific anti-C 1-inh antiserum and determine the concentration ofCl by its amidolytic activity towards a synthetic tripeptide substrate.
We have shown that our assay specifically determines the concentration of activated Cl in plasma, and not CI complexed to inhibitors. Thus, a precise and simple assessment of the functional capacity in plasma of the first complement component of the classical complement pathway is now possible.
Materials and Methods

Matenals
We prepared an imidazole hydrochloride buffer (pH 8.0, ionic strength 20 mmolJL at 37 #{176}C) containing, per liter, 0. Other reagents were purified CIs (Biopool), nonspecific human IgG (Dakopatts), purified C1-inh (Behringwerke AG, Marburg, F.R.G.), and antiserum to Cir (Calbiochem, San Diego, CA).
We assessed in serum the hemolytic activity initiated by activation of the classical complement pathway, expressed as the 50% hemolysis point (CH), according to Kabat and Mayer (17) . in the specificity experiments. Functional C1-inh activities in plasma were assessed by a chromogenic assay as reported previously (16) .
Samples
Blood samples for preparation of plasma were collected into siliconized evacuated glass tubes (Venoject T-273 QS;
Terumo Europa SA, Leuven, Belgium) containing tripotassium EDTA to remove Ca2 and dissociate the Cl complex into its stable subeomponents Clq, Clr, and Cis (3 mL of blood was mixed with 0.06 mL of 0.17 molfL EDTA reagent). This procedure was necessary to prevent activation of Cl by immune complexes and activated clotting factors (see below). Also, the Cl-C 1-mb complexes remain stable in the presence of EDTA (18) . Without delay, samples were placed in an ice-bath; within 10 min, the platelet-poor plasma was prepared by centrifugation in the cold at 2000 x g for 20 mm. Serum samples prepared for the experiments were collected in 5-mL plain evacuated glass tubes (Venoject VT-050 U; Terumo Europa SA), placed at room temperature for 30 mm, and centrifuged at 2000 x g (25 #{176}C) for 20 mm. Plasma and serum specimens were stored at -70 #{176}C until assay.
Plasma samples were obtained from blood drawn in the morning from 19 apparently healthy volunteers (12 women and seven men, ages 24-53 years) with no medical history of coagulation problems and taking no medications, including oral contraceptives.
The samples were pooled before storage at -70 #{176}C and used to construct in-house calibration curves. We defined a 200% concentration of Cl in plasma as the amidolytic activity measured in plasma that had been diluted with the imidazole buffer, five volumes of plasma per three volumes of buffer ( Figure 1 ). To estimate the variability of the amidolytic activity when the calibrating pool was renewed, we constructed calibration curves from five different lots of pooled human plasma prepared as described and collected over a period of five years. The calculated variance, expressed as SD/ , in each point of dilution ( Figure 1 ) was <6%. Morning samples were also collected from 36 fasting, apparently healthy individuals
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Absorbance (iA/min x 100) (23 women and 13 men, ages 15-62 years) and from 4 patients (33 women and 11 men, ages 15-57 years): 1 patients with a connective tissue disease and 28 patienti with sepsis. Serum specimens for determination of hemo lytic activity were available from all the patients with connective tissue disease and from 25 of the 36 norma individuals.
Patients and volunteers gave their informed consen before blood sampling.
Chromogenic Assay of Cl Activity
In this assay, we utilize the activation of Cl that follow the functional inhibition of C1-inh by adding antibodies ti C1-inh to the sample (2, 15) . After maximal activation, Cl is determined by an amidolytic rate assay. Optimized at described below, the conditions and volumes were adjustec for use with the Cobas-Bio centrifugal analyzer (Hoifmann La Roche, Basel, Switzerland)
as follows: Dilute plasmC samples with the imidazole buffer 
(A/min). Assay conditions as in Materials and Methods
Unless otherwise stated, data are presented as meant (and 1 SD). Paired and unpaired Student's t-test was used to evaluate differences within and between groups, respec tively. Analysis of variance was used to estimate thE variation in predicted y-values around the y-intercept ol the regression line (method of least squares).
Results
Assay Optimization
Incubation time and kinetics. With no preincubatio period, we added to plasma at the same time the monospe cific antiserum to C1-inh and the substrate ( Figure 2 ) Absorbances increased linearly with reaction time from 2 mm to 36 mm, after which the rate decreased, presumabl because the synthetic substrate was depleted ( to plasma an identical concentration of nonspecific IgG and observed no activation of Cl ( Figure 5) . Furthermore, the amidolytic activity in unactivated plasma was negligible (buffer curve, Figure 5 ). The difference in the initial absorbances when antibody to C1-inh, instead of pure buffer, is added to plasma (A0 in Figure 5 ) is probably due to the generation of light-absorbing complexes. However, the background absorbance is of minor importance for the precision of our assay because we make use of initial rate kinetics (A/min).
Ionic strength and pH of the imidazole hydrochloride buffer. We found the optimum range of the ionic strength of the buffer to be 20 to 200 mmolJL for preparing the solution of the substrate (data not shown). In the reaction between plasma and the antiserum to C1-inh, the recorded amidolytic activities depended on the ionic strength ( Figure 6 ). We therefore adjusted the ionic strength of the imidazole buffer to 20 mmol/L. Also, the recorded amidolytic activity was highly pH dependent ( Figure 6 ), necessitating adjustment to pH 8.0 in the buffer. However, if antiserum to Clr was added to the activated plasma, the amidolytic activity (A/min) was negligible ( Figure 7 ). These findings indicate that both Cir and CIs contribute to the recorded amidolytic activity and that activation of Clr is a prerequisite for the activation of Cis. The reduction in amidolytic activity after the addition of antiserum to Cls and the elimination of amidolytic activity after addition of the antiserum to Cir strongly suggest that our assay is specific for Cl in plasma.
In agreement with previous observations (19), we obAbsorbonce (A) Absorbance (iA/min x 100) 
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.0/ served that a factor(s) generated by coagulation of normal blood activates Cl (Figure 8 ). In unactivated, normal, pooled serum, the anndolytic activity increased significantly with time, in contrast to the negligible activity in the corresponding unactivated, normal, pooled plasma (Figures 5 and 8 ). This was also the case when EDTA was added to the serum to the same concentration as in plasma (Figure 8 ). These experiments suggest that the generation of a.midolytic activity in serum is not caused by activation of Cl by immune complexes (20) but rather is related to the activation of clotting factors.
Precision studies and reference interval. The estimated interassay variation (CV) was 5% (n = 20) and the intraassay CV was 1% (n = 24). The plasma sample with the recorded lowest C1-inh activity (43%) relative to normal, pooled plasma was supplemented with purified Cl-inh to yield relative Cl-inh concentrations of 43%, 80%, 110%, 140%, 170%, and 200%, respectively.
We found at all these C1-inh activities in plasma a constant concentration of Cl in plasma (42%; range 40-44%, which is within the interassay variation). This finding is of particular importance and indicates that a concentration of C1-inh up to 200% of that in normal, pooled plasma under our experimental conditions does not significantly influence the assessment of plasma Cl activity. We estimated the average value and reference range (mean ± 2 SD) for Cl in plasma from 36 normal controls to be 96% (70-122%).
Application of the Assay
The hemolytic activity in serum (CH50) correlated significantly with the amidolytic activity of Cl in plasma in the patients with a connective tissue disease and in the apparently healthy individuals (r = 0.55, t = 4.09, P <0.001; Figure 9 ). In addition, we observed a highly significant correlation in plasma between the antigen concentrations ofCls and the amidolytic activities ofCl (r = 0.72, t = 9.47, P <0.001; Figure 9 ). Analysis of variance demonstrated that the estimated y-intercept of the regression line (y = 0.72x + 13.8%) included the point of origin (Figure 9 ). In apparently healthy individuals, the mean (and SD) value of Cl activity and Cis antigen concentration in plasma did not differ significantly:
96% (13%) and 95% (10%), respectively (t = -0.91, P >0.60). In contrast, the patients' group was characterized by significantly lower CT activities than Cls antigen concentrations in plasma: 76% (32%) and 102% (35%), respectively (t = -9.81, P <0.001). The latter difference between Cl activities and Cis antigen concentrations in plasma can be explained by the occurrence of in vivo-generated Cl-C1-inh complexes in the plasma samples (18, 21) . This conclusion provides evidence that we have determined the concentration of free activated Cl in plasma and not of the Cl bound to C1-inh.
The mean activity of Cl in plasma ( Figure 10 ) was significantly lower in the patients with a connective-tissue disease and sepsis than in the apparently healthy individuals: 76% (32%) vs 96% (13%) (t = -3.08, P <0.01). The high concentrations of Cl recorded in some of the patients (Figure 10 ) are probably related to the increase of complement proteins in the blood as part of the acute-phase response (22, 23).
Discussion
We have developed a new functional assay of Cl in plasma stabilized by EDTA, based on the activation of Cl through the inhibition of C1-irih (2, 15). By adding monospecific IgG antibodies to C1-inh to the plasma, we eliminate the functional C1-inh in the sample (Figure 4 ) and at the same time initiate the activation of Cl. After maximal activation (Figure 2) , we determine the activity of Cl with an amidolytic rate assay. In the optimized assay the final substrate concentration of 0.36 mmoIIL is fivefold lower than the estimated KM of the system (Figure 3 ), but still sufficient to yield a constant rate of substrate hydrolysis.
The linear curve during the period of assay (Figures 2 and  5) indicates the presence of sufficient excess of the synthetic substrate.
Therefore, we conclude that the laws of initial rate kinetics are obeyed in the assay system as described (24) . Our experiments on assay specificity strongly suggest that, with the substrate we used, both Clr and CIs contribute to the recorded amidolysis [Clq has no known enzymatic activity (1)1 so that we are recording specifically the concentration of Cl in plasma ( Figure 7) . Furthermore, our method determines the available functional plasma concentration of Cl, not the CT-Cl-inh complexes, which in serum specimens. These observations may help to explain why our method has a much lower imprecision than the conventionally used biological assay (10) (11) (12) (13) (14) . In addition, our functional assay of Cl in plasma is more sensitive than the hemolytic assay for the classical complement pathway, considered to be the reference method (17) . Thus, we could obtain detectable absorbances on our reference curve corresponding to a relative concentration as low as 25% of that in normal plasma (Figure 1 ), whereas the lower detection limit of the hemolytic assay seems to be about only 50% of the concentration of Cl in plasma (Figure 9) . Nonetheless, we could validate our method against the hemolytic assay ( Figure 9 ) as well as detect classical complement pathway activation in pathophysiological states ( Figure 10 ).
Our assay for detecting free activated Cl in plasma should prove useful for investigating diseases with classical complement activation (3) (4) (5) (6) (7) (8) (9) 25) and the interrelation between complement and coagulationiflbrinolysis (26) . In the routine laboratory, it should be useful for screening individuals for inherited Cl deficiency (27) and for the differential diagnosis between hereditary and acquired angioneurotic edema, all patients with the latter condition having low concentrations of Cl (28) .
